论文部分内容阅读
柳氨苄心定(Labetalol 以下简称 Lab)是一种兼有α受体阻滞作用的新型β受体阻滞剂,欧美于1975年起临床用于治疗高血压。该药对轻、中、重度高血压口服有效,静脉
Salicylate (Labetalol, hereinafter referred to as Lab) is a new type of β-blocker with both α-blocker effect and clinical use in Europe and the United States since 1975 for the treatment of hypertension. The drug is effective in oral administration of light, moderate and severe hypertension